A Bayesian approach to sharing information on sensitivity of a Multi-Cancer Early Detection test across and within tumour types and stages

Sofia Dias; Yiwen Liu; Stephen Palmer; Marta O Soares

doi:10.48550/arXiv.2504.21517

A Bayesian approach to sharing information on sensitivity of a Multi-Cancer Early Detection test across and within tumour types and stages

Sofia Dias, Yiwen Liu, Stephen Palmer, Marta O Soares

Research output: Working paper › Preprint

Abstract

The Galleri (R) (GRAIL) multi-cancer early detection test measures circulating tumour DNA (ctDNA) to predict the presence of more than 50 different cancers, from a blood test. If sensitivity of the test to detect early-stage cancers is high, using it as part of a screening programme may lead to better cancer outcomes, but available evidence indicates there is heterogeneity in sensitivity between cancer types and stages. We describe a framework for sharing evidence on test sensitivity between cancer types and/or stages, examining whether models with different sharing assumptions are supported by the evidence and considering how further data could be used to strengthen inference. Bayesian hierarchical models were fitted, and the impact of information sharing in increasing precision of the estimates of test sensitivity for different cancer types and stages was examined. Assumptions on sharing were informed by evidence from a review of the literature on the determinants of ctDNA shedding and its detection in a blood test. Support was strongest for the assumption that sensitivity can be shared only across stage 4 for all cancer types. There was also support for the assumption that sensitivities can be shared across cancer types for each stage, if cancer types expected to have low sensitivity are excluded which increased precision of early-stage cancer sensitivity estimates and was considered the most appropriate model. High heterogeneity limited improvements in precision. For future research, elicitation of expert opinion could inform more realistic sharing assumptions.

Original language	Undefined/Unknown
Publisher	arXiv
DOIs	https://doi.org/10.48550/arXiv.2504.21517
Publication status	Published - 30 Apr 2025

Bibliographical note

link to code: https://github.com/MCED-Galleri-HealthEconomicEval-Program/BayesianModelTestSens-1

Keywords

stat.ME

Access to Document

10.48550/arXiv.2504.21517Licence: CC BY

2504.21517v1

Cite this

@techreport{819d05fc59dd49109971bc68df55ebf0,

title = "A Bayesian approach to sharing information on sensitivity of a Multi-Cancer Early Detection test across and within tumour types and stages",

abstract = "The Galleri (R) (GRAIL) multi-cancer early detection test measures circulating tumour DNA (ctDNA) to predict the presence of more than 50 different cancers, from a blood test. If sensitivity of the test to detect early-stage cancers is high, using it as part of a screening programme may lead to better cancer outcomes, but available evidence indicates there is heterogeneity in sensitivity between cancer types and stages. We describe a framework for sharing evidence on test sensitivity between cancer types and/or stages, examining whether models with different sharing assumptions are supported by the evidence and considering how further data could be used to strengthen inference. Bayesian hierarchical models were fitted, and the impact of information sharing in increasing precision of the estimates of test sensitivity for different cancer types and stages was examined. Assumptions on sharing were informed by evidence from a review of the literature on the determinants of ctDNA shedding and its detection in a blood test. Support was strongest for the assumption that sensitivity can be shared only across stage 4 for all cancer types. There was also support for the assumption that sensitivities can be shared across cancer types for each stage, if cancer types expected to have low sensitivity are excluded which increased precision of early-stage cancer sensitivity estimates and was considered the most appropriate model. High heterogeneity limited improvements in precision. For future research, elicitation of expert opinion could inform more realistic sharing assumptions.",

keywords = "stat.ME",

author = "Sofia Dias and Yiwen Liu and Stephen Palmer and Soares, {Marta O}",

note = "link to code: https://github.com/MCED-Galleri-HealthEconomicEval-Program/BayesianModelTestSens-1",

year = "2025",

month = apr,

day = "30",

doi = "10.48550/arXiv.2504.21517",

language = "Undefined/Unknown",

publisher = "arXiv",

type = "WorkingPaper",

institution = "arXiv",

}

TY - UNPB

T1 - A Bayesian approach to sharing information on sensitivity of a Multi-Cancer Early Detection test across and within tumour types and stages

AU - Dias, Sofia

AU - Liu, Yiwen

AU - Palmer, Stephen

AU - Soares, Marta O

N1 - link to code: https://github.com/MCED-Galleri-HealthEconomicEval-Program/BayesianModelTestSens-1

PY - 2025/4/30

Y1 - 2025/4/30

N2 - The Galleri (R) (GRAIL) multi-cancer early detection test measures circulating tumour DNA (ctDNA) to predict the presence of more than 50 different cancers, from a blood test. If sensitivity of the test to detect early-stage cancers is high, using it as part of a screening programme may lead to better cancer outcomes, but available evidence indicates there is heterogeneity in sensitivity between cancer types and stages. We describe a framework for sharing evidence on test sensitivity between cancer types and/or stages, examining whether models with different sharing assumptions are supported by the evidence and considering how further data could be used to strengthen inference. Bayesian hierarchical models were fitted, and the impact of information sharing in increasing precision of the estimates of test sensitivity for different cancer types and stages was examined. Assumptions on sharing were informed by evidence from a review of the literature on the determinants of ctDNA shedding and its detection in a blood test. Support was strongest for the assumption that sensitivity can be shared only across stage 4 for all cancer types. There was also support for the assumption that sensitivities can be shared across cancer types for each stage, if cancer types expected to have low sensitivity are excluded which increased precision of early-stage cancer sensitivity estimates and was considered the most appropriate model. High heterogeneity limited improvements in precision. For future research, elicitation of expert opinion could inform more realistic sharing assumptions.

AB - The Galleri (R) (GRAIL) multi-cancer early detection test measures circulating tumour DNA (ctDNA) to predict the presence of more than 50 different cancers, from a blood test. If sensitivity of the test to detect early-stage cancers is high, using it as part of a screening programme may lead to better cancer outcomes, but available evidence indicates there is heterogeneity in sensitivity between cancer types and stages. We describe a framework for sharing evidence on test sensitivity between cancer types and/or stages, examining whether models with different sharing assumptions are supported by the evidence and considering how further data could be used to strengthen inference. Bayesian hierarchical models were fitted, and the impact of information sharing in increasing precision of the estimates of test sensitivity for different cancer types and stages was examined. Assumptions on sharing were informed by evidence from a review of the literature on the determinants of ctDNA shedding and its detection in a blood test. Support was strongest for the assumption that sensitivity can be shared only across stage 4 for all cancer types. There was also support for the assumption that sensitivities can be shared across cancer types for each stage, if cancer types expected to have low sensitivity are excluded which increased precision of early-stage cancer sensitivity estimates and was considered the most appropriate model. High heterogeneity limited improvements in precision. For future research, elicitation of expert opinion could inform more realistic sharing assumptions.

KW - stat.ME

U2 - 10.48550/arXiv.2504.21517

DO - 10.48550/arXiv.2504.21517

M3 - Preprint

BT - A Bayesian approach to sharing information on sensitivity of a Multi-Cancer Early Detection test across and within tumour types and stages

PB - arXiv

ER -